Advanced Biomed (NASDAQ: ADVB) launches A+PerfusC 3D cell platform

Rhea-AI Filing Summary

Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 00000 0001941029 0001941029 2025-09-19 2025-09-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

September 19, 2025

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada		001-42548		87-2177170
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

Item 7.01 Regulation FD Disclosure.

On September 19, 2025, the Company issued a press release regarding the launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery. A copy of the press release is attached as Exhibit 99.1 hereto.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this report in such filing.

Item 9.01 Financial Statement and Exhibits.

Exhibit No.		Description
99.1*		Press Release, dated September 19, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.
Date: September 19, 2025	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

2

FAQ

What did Advanced Biomed (ADVB) disclose in its latest 8-K filing?

Advanced Biomed disclosed that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform. The filing primarily serves to furnish this press release as an exhibit under a Regulation FD disclosure item.

What is A+PerfusC™ as mentioned by Advanced Biomed (ADVB)?

A+PerfusC™ is described as an integrated perfusion 3D cell culture platform for precision medicine and drug discovery. Advanced Biomed’s filing notes its launch and provides the related press release as an exhibit, but does not include additional technical or commercial details in the text provided.

Which exhibit did Advanced Biomed (ADVB) attach related to the A+PerfusC™ launch?

Advanced Biomed attached Exhibit 99.1, a press release dated September 19, 2025, covering the launch of A+PerfusC™. The company also included Exhibit 104, a cover page interactive data file embedded within the Inline XBRL document for regulatory formatting and disclosure purposes.

Is the A+PerfusC™ press release deemed filed or furnished by Advanced Biomed (ADVB)?

The A+PerfusC™ press release is being furnished, not filed, under Regulation FD. Advanced Biomed states it will not be deemed filed for Section 18 liability or automatically incorporated into Securities Act or Exchange Act filings unless specifically referenced later.

Who signed the Advanced Biomed (ADVB) report about the A+PerfusC™ launch?

The report was signed on behalf of Advanced Biomed Inc. by Yi Lu, the company’s Chief Executive Officer. This signature confirms the company’s authorization of the disclosure regarding the A+PerfusC™ platform press release and the furnished exhibits included with the current report.